Vifor Pharma (SIX Swiss Exchange:VIFNI) (SIN:CH0364749348) disclosed on Monday that it has agreed to acquire the priority review voucher (PRV) from US Food and Drug Administration (FDA).
The company stated that the PRV entitles the holder to obtain priority review for a New Drug Application or Biologics License Application thereby reducing the target review time and potentially leading to a faster approval.
This transaction is subject to customary closing conditions and clearance under the Hart-Scott Rodino (HSR) Antitrust Improvements Act.
Headquartered in Switzerland, the pharmaceuticals company is engaged in iron deficiency, nephrology and cardio-renal therapies. It said it strives to help patients around the world with severe and chronic diseases to lead better, healthier lives.
Egetis receives US notice of allowance for MCT8 deficiency composition patent
Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117